Marksans Pharma defers ₹100 cr capex as spare capacity holds
Management sticks to its ₹4,000 cr revenue target for FY28 despite facing raw material inflation of 20-25%.
— 2 earlier stories on Marksans Pharma Ltd. →What's new
- Marksans Pharma is pausing a ₹100 cr capacity expansion project.
- Management cites sufficient existing spare capacity as the reason for the delay.
- The company maintains its FY28 revenue target of ₹4,000 cr.
Why this matters
Deferring capital expenditure preserves cash flow when current assets are underutilized. The company must now manage margin pressure from 20-25% raw material inflation without the benefit of new, more efficient capacity.
What we're watching
- Whether raw material inflation forces a revision to margin guidance.
- Updates on the M&A pipeline mentioned during the call.
- Utilization rates of existing facilities in upcoming quarterly reports.
The full read
Marksans Pharma is hitting the brakes on a ₹100 crore capacity expansion project. Management confirmed the deferral during its recent conference call, noting that current facilities have enough spare capacity to handle existing demand.
It is a prudent move.
Despite this pause, the company remains committed to its ₹4,000 crore revenue goal for FY28. The path to that target is getting more expensive, however, as management flagged raw material inflation in the 20-25% range. The call also touched on ongoing M&A due diligence, though no specific deals were announced. This summary provides a record of the company's strategic outlook, as the primary results were already disclosed in earlier filings. The immediate test for the company is maintaining margins while navigating double-digit cost inflation without the efficiency gains of new capacity.
Questions answered
- Why did Marksans Pharma defer its ₹100 crore capex?
- The company determined that its existing facilities have sufficient spare capacity to meet current demand, making the planned expansion unnecessary for now.
- What is the company's outlook for FY28?
- Management maintains its target of reaching ₹4,000 crore in revenue by FY28.
- What cost pressures is the company facing?
- Management reported that raw material inflation is currently running between 20% and 25%.
- Does this filing contain new financial results?
- No. This summary covers a conference call regarding previously disclosed Q4 and FY26 results.
Story so far
All notes on MARKSANS →- 27 May 2026 · 5:41 PM IST Marksans Pharma defers ₹100 cr capex as spare capacity holds
- 1d ago Marksans Pharma profit jumps 60% on standalone basis for FY26
- 1d ago Marksans Pharma profit climbs 60% on standalone basis for FY26